



ESMO Preceptorship on Colorectal Cancer

22-23 May 2014
Prague, Czech Republic



SÃO JOÃO

Metastatic Colorectal Cancer - a case of long-term survival -

Ana Catarina Fernandes
Medical Oncology Resident

São João Hospital Centre
Porto - Portugal



41 years old, Female

Irrelevant Medical History

September
2003

Began symptoms of:

Abdominal pain + change in bowel habits
(alternating periods of constipation with diarrhea)

Oct/2003

Colonoscopy: Transverse colon Adenocarcinoma (**Biopsy**)

Oct/2003

CT scan: single liver lesion (65 mm) in segment V. No other alterations.



41 years old, Female

Irrelevant Medical History

September
2003

Began symptoms of:

Abdominal pain + change in bowel habits
(alternating periods of constipation with diarrhea)

Oct/2003

Colonoscopy: Transverse colon Adenocarcinoma (**Biopsy**)

Oct/2003

CT scan: single liver lesion (65 mm) in segment V. No other alterations.

19/Nov
2003

Segmental colectomy

Adenocarcinoma, moderately differentiated
Lymphatic and venous invasion
16 non-metastatic lymph nodes
pT3N0R0
K-RAS wild type

Chemotherapy: 6 cycles of FOLFOX



**26/Mar
2004**

Segment V hepatic metastasectomy (R0)

Chemotherapy: 6 cycles of FOLFOX



**26/Mar
2004**

Segment V hepatic metastasectomy (R0)

Chemotherapy: 6 cycles of FOLFOX

6 years Disease Free Survival

26/Mar
2004



Segment V hepatic metastasectomy (R0)

Chemotherapy: 6 cycles of FOLFOX

6 years Disease Free Survival

Nov
2010

CT scan: single liver lesion of 55 mm in the left lobe. No other alterations.



26/Mar
2004


Segment V hepatic metastasectomy (R0)

Chemotherapy: 6 cycles of FOLFOX

6 years Disease Free Survival

Nov
2010

CT scan: single liver lesion of 55 mm in the left lobe. No other alterations.



26/Mar
2004


Segment V hepatic metastasectomy (R0)

Chemotherapy: 6 cycles of FOLFOX

6 years Disease Free Survival

Nov
2010

CT scan: single liver lesion of 55 mm in the left lobe. No other alterations.



3/Dec
2010

Segment III hepatic metastasectomy (R0)

Chemotherapy: 12 cycles of FOLFOX



23 months Disease Free Survival



23 months Disease Free Survival

Nov/2012


CT scan: pulmonary lesion in the right upper lobe of 9 mm. > 4 hepatic lesions in the left lobe, segments IV and VII. No other alterations.



23 months Disease Free Survival

Nov/2012

CT scan: pulmonary lesion in the right upper lobe of 9 mm. > 4 hepatic lesions in the left lobe, segments IV and VII. No other alterations.




Chemotherapy: 6 cycles of FOLFIRI + Cetuximab

23 months Disease Free Survival

Nov/2012


CT scan: pulmonary lesion in the right upper lobe of 9 mm. > 4 hepatic lesions in the left lobe, segments IV and VII. No other alterations.



Chemotherapy: 6 cycles of FOLFIRI + Cetuximab

Jan/2013




CT scan: reduced lung lesion from 9 mm to 6 mm. Only 2 hepatic lesions in the left lobe; disappearance of the remaining hepatic lesions.



23 months Disease Free Survival

Nov/2012


CT scan: pulmonary lesion in the right upper lobe of 9 mm. > 4 hepatic lesions in the left lobe, segments IV and VII. No other alterations.



Chemotherapy: 6 cycles of FOLFIRI + Cetuximab

Jan/2013

CT scan: reduced lung lesion from 9 mm to 6 mm. Only 2 hepatic lesions in the left lobe; disappearance of the remaining hepatic lesions.



Mar/2013

FDG PET/CT: 2 hepatic lesions in the left lobe. No extrahepatic metastases.



**4/April
2013**

**Left lobectomy
Hepatic metastasectomy segments IV, V, VI and VIII (R0)**

Chemotherapy: 8 cycles of FOLFIRI + Cetuximab

7 months Disease Free Survival

4/April
2013


Left lobectomy
Hepatic metastasectomy segments IV, V, VI and VIII (R0)

Chemotherapy: 8 cycles of FOLFIRI + Cetuximab

7 months Disease Free Survival

Nov
2013

CT scan: several bilateral pulmonay lesions.





**4/April
2013**

**Left lobectomy
Hepatic metastasectomy segments IV, V, VI and VIII (R0)**

Chemotherapy: 8 cycles of FOLFIRI + Cetuximab

7 months Disease Free Survival

**Nov
2013**

CT scan: several bilateral pulmonay lesions.

Chemotherapy: 5 cycles of FOLFIRI + Cetuximab



**4/April
2013**

**Left lobectomy
Hepatic metastasectomy segments IV, V, VI and VIII (R0)**

Chemotherapy: 8 cycles of FOLFIRI + Cetuximab

7 months Disease Free Survival

**Nov
2013**

CT scan: several bilateral pulmonay lesions.

Chemotherapy: 5 cycles of FOLFIRI + Cetuximab

**March
2014**

CT scan: stable pulmonary lesions. New hepatic lesions in the segments VII and V. Metastatic bone lesions in the sternum and D9.

Chemotherapy: FOLFIRI + Bevacizumab



4/April
2013

Left lobectomy
Hepatic metastasectomy segments IV, V, VI and VIII (R0)

Chemotherapy: 8 cycles of FOLFIRI + Cetuximab

7 months Disease Free Survival

Nov
2013

CT scan: several bilateral pulmonay lesions.

Chemotherapy: 5 cycles of FOLFIRI + Cetuximab

March
2014

CT scan: stable pulmonary lesions. New hepatic lesions in the segments VII and V. Metastatic bone lesions in the sternum and D9.

Chemotherapy: FOLFIRI + Bevacizumab

Today

She keeps chemotherapy treatments with **FOLFIRI + Bevacizumab** with good tolerance.

Metastatic colon cancer with 10 years of Overall Survival

Discussion...

1. **The treatment goal** should always be well defined before any **plan decision** and reassessed during disease evolution.
2. **In KRAS wt patients, with potentially resectable metastatic disease** (group 1) **first-line** treatment should be with **EGFR inhibitors** plus Chemotherapy, since response rate seems to be higher.
3. **How many times can we try to “cure” a metastatic colorectal cancer? Who defines the limit?**
 1. The Medical Oncologist?
 2. The Surgeon?
 3. The Patient?
 4. The Disease...



